These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28135854)

  • 1. Pharmacological therapies for Liposarcoma.
    Saponara M; Stacchiotti S; Gronchi A
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):361-377. PubMed ID: 28135854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current management options for liposarcoma and challenges for the future.
    Kollár A; Benson C
    Expert Rev Anticancer Ther; 2014 Mar; 14(3):297-306. PubMed ID: 24397249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
    Suarez-Kelly LP; Baldi GG; Gronchi A
    Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
    [No Abstract]   [Full Text] [Related]  

  • 4. Eribulin in advanced liposarcoma and leiomyosarcoma.
    Setola E; Noujaim J; Benson C; Chawla S; Palmerini E; Jones RL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):717-723. PubMed ID: 28621163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New frontiers in the treatment of liposarcoma, a therapeutically resistant malignant cohort.
    Hoffman A; Lazar AJ; Pollock RE; Lev D
    Drug Resist Updat; 2011 Feb; 14(1):52-66. PubMed ID: 21169051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing Liposarcomas: Cutting Through the Fat.
    Manji GA; Schwartz GK
    J Oncol Pract; 2016 Mar; 12(3):221-7. PubMed ID: 26962163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
    Thway K; Flora R; Shah C; Olmos D; Fisher C
    Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma.
    Crago AM; Singer S
    Curr Opin Oncol; 2011 Jul; 23(4):373-8. PubMed ID: 21552124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposarcoma: Multimodality Management and Future Targeted Therapies.
    Crago AM; Dickson MA
    Surg Oncol Clin N Am; 2016 Oct; 25(4):761-73. PubMed ID: 27591497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
    Schöffski P
    Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.
    Lesovaya EA; Fetisov TI; Bokhyan BY; Maksimova VP; Kulikov EP; Belitsky GA; Kirsanov KI; Yakubovskaya MG
    Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New targeted therapies in liposarcoma: state of art and future perspectives.
    Franza A; Fabbroni C; Pasquali S; Casali PG; Sanfilippo R
    Curr Opin Oncol; 2024 Jul; 36(4):291-296. PubMed ID: 38726840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dedifferentiated Liposarcoma: Systemic Therapy Options.
    Gahvari Z; Parkes A
    Curr Treat Options Oncol; 2020 Feb; 21(2):15. PubMed ID: 32026050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
    Kobayashi E; Kawai A
    Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of molecular biology to individualize therapy for patients with liposarcoma.
    Abbas Manji G; Singer S; Koff A; Schwartz GK
    Am Soc Clin Oncol Educ Book; 2015; ():213-8. PubMed ID: 25993159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma.
    Chung L; Lau SK; Jiang Z; Loera S; Bedel V; Ji J; Weiss LM; Chu PG
    Am J Surg Pathol; 2009 Nov; 33(11):1594-600. PubMed ID: 19574885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunoreactivity of p53, mdm2, and p21WAF1 in dedifferentiated liposarcoma: special emphasis on the distinct immunophenotype of the well-differentiated component.
    Adachi T; Oda Y; Sakamoto A; Saito T; Tamiya S; Masuda K; Tsuneyoshi M
    Int J Surg Pathol; 2001 Apr; 9(2):99-109. PubMed ID: 11484509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medical treatment of advanced chordomas.
    Colia V; Stacchiotti S
    Eur J Cancer; 2017 Sep; 83():220-228. PubMed ID: 28750274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
    De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
    Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complete response of a recurrent-metastatic liposarcoma with dedifferentiated histological features following the administration of trabectedin and review of literature.
    Kus T; Aktas G; Kalender ME; Tutar E; Ulker E; Camci C
    J Cancer Res Ther; 2015; 11(4):974-6. PubMed ID: 26881560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.